Egypt’s Oncology drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
In Egypt, noncommunicable diseases are responsible for 85% of deaths, with cancers representing the second most common cause of mortality (14%) after cardiovascular diseases (46%). It has an ambitious plan for preventing and controlling non-communicable diseases, including cancer, which was initiated in 2018 (known as the Egypt National Multisectoral Action Plan for Prevention and Control of Noncommunicable Diseases).
In 2020, there were about 134642 new cancer cases and 89,042 cancer-related deaths in Egypt. Liver and breast cancers are the most common tumors in terms of incidence and mortality.
Patients with cancer in Egypt receive their treatment in General Authority for Health Insurance hospitals, in Ministry of Health and Population or university hospitals at the government’s expense, or in the private sector at their own expense or with personal insurance coverage.
The estimated trends for breast and lung cancer in Egypt are projected to rise in the future. According to World Health Organization’s Egypt’s profile for cancer, the breast cancer cases might go up to 40, 544 by 2040 as compared to the 23,081 cases in 2018. For Lung cancer this figure might go up to 11, 945 cases by 2040 as compared to the 6,045 reported cases in 2018.
Such a rise in the prevalence of cancer among the population is likely to drive the market growth for Oncology Therapeutics in Egypt.
Further, the introduction of the Universal Health Insurance Law by the government in 2018 will see an increase in the number of health institutions and facilities, as the government pledges to take care of non-communicable diseases including cancer which has been a major part of the existing disease burden in Egypt. Such initiatives are forecasted to be a positive growth sign for the oncology therapeutics market in the country.